These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31631965)

  • 21. Effect of Topical Recombinant Human Nerve Growth Factor on Corneal Epithelial Regeneration in Refractory Epithelial Keratopathy.
    Dai X; Tunc U; Zhu X; Karakus S
    Ocul Immunol Inflamm; 2024 Mar; ():1-7. PubMed ID: 38427335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real Life Data on Efficacy and Safety of Topical NGF Eye Drops (Cenegermin).
    Zwingelberg SB; Bachmann BO; Cursiefen C
    Klin Monbl Augenheilkd; 2020 Dec; 237(12):1455-1461. PubMed ID: 33285589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy.
    Riva I; Micheletti E; Fausto R; Bruttini C; De Angelis G; Ceccuzzi R; Quaranta L
    Eur J Ophthalmol; 2022 Jul; 32(4):NP78-NP81. PubMed ID: 33657894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation.
    Sacchetti M; Komaiha C; Bruscolini A; Albanese GM; Marenco M; Colabelli Gisoldi RAM; Pocobelli A; Lambiase A
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):917-925. PubMed ID: 34633522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database.
    Li Y; Yang H; Gao Y; He W
    Expert Opin Drug Saf; 2024 Mar; 23(3):385-391. PubMed ID: 37608598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.
    Hamrah P; Yavuz Saricay L; Ozmen MC
    Cornea; 2022 Jun; 41(6):673-679. PubMed ID: 35266655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy.
    Balbuena-Pareja A; Bogen CS; Cox SM; Hamrah P
    Front Neurosci; 2023; 17():1210179. PubMed ID: 37965220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aftermarket effects of cenegermin for neurotrophic keratopathy in pediatric patients.
    Hatcher JB; Soifer M; Morales NG; Farooq AV; Perez VL; Shieh C
    Ocul Surf; 2021 Jul; 21():52-57. PubMed ID: 33887453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment of a Pediatric Neurotrophic Keratopathy With Cenegermin.
    Papadopoulos K; Besgen V; Sekundo W
    Cornea; 2021 Apr; 40(4):516-518. PubMed ID: 32947402
    [